FDA Approves Pembrolizumab Plus Axitinib in Advanced Kidney Cancer
Does Bladder-Sparing Therapy Plus Vinorelbine Improve Survival in Cisplatin-Ineligible Patients?
Accelerated FDA Approval Granted to Erdafitinib for Metastatic Urothelial Carcinoma
AACR 2019: Can B Cells Predict Response to Immunotherapy in Renal Cell Carcinoma?
Does Tumor Thrombus Affect Outcomes With Cytoreductive Nephrectomy?
KEYNOTE-426 Trial: Pembrolizumab Plus Axitinib Versus Sunitinib in Advanced Kidney Cancer
Cabozantinib in Advanced Non–Clear Cell Kidney Cancer
Individualized Sunitinib Therapy for Patients With Metastatic Kidney Cancer
Advanced Renal Cell Carcinoma: combination, sequential strategies, & immunotherapy
Optimizing Outcomes in mRCC: Finding the Balance of Immune Inhibition (login required)
Sequencing and Transitions for Advanced Renal Cell Carcinoma: Leveraging the Latest Tools and Managing Complications
Finding Answers to the Important Questions: Sequencing and Optimizing QoL in mRCC (login required)
Fox Chase Cancer Center
UCSF Helen Diller Family Comprehensive Cancer Center
UC San Diego Moores Cancer Center
Robert H. Lurie Comprehensive Cancer Center of Northwestern University
Lenvatinib Plus Everolimus (Kidney Cancer)
Nivolumab + Ipilimumab (Renal Cell Carcinoma)
NCCN Guidelines for Patients Kidney Cancer—Quick Guide
American Cancer Society: Kidney Cancer
Urology Care Foundation
American Society of Clinical Oncology: Kidney Cancer